Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy

Over 55,000 people in the United States are diagnosed with pancreatic ductal adenocarcinoma (PDAC) yearly, and fewer than 20% of these patients survive a year beyond diagnosis. Chemotherapies are considered or used in nearly every PDAC case, but there is limited understanding of the complex signalin...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JCI Insight
Autori principali: Lipner, Matthew B., Peng, Xianlu L., Jin, Chong, Xu, Yi, Gao, Yanzhe, East, Michael P., Rashid, Naim U., Moffitt, Richard A., Herrera Loeza, Silvia G., Morrison, Ashley B., Golitz, Brian T., Vaziri, Cyrus, Graves, Lee M., Johnson, Gary L., Yeh, Jen Jen
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2020
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7205424/
https://ncbi.nlm.nih.gov/pubmed/32213714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.129905
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi